AstraZeneca results offer chance to set itself apart from rivals after FTSE 100 crown slipsProactive Investors • 11/02/23
AstraZeneca Partners With Axis Communications to Improve Security and Enhance Operational Efficiency at Maryland R&D FacilityBusiness Wire • 11/01/23
Cellectis' stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZenecaMarket Watch • 11/01/23
These healthcare stocks should come to life as boomers live their golden yearsMarket Watch • 10/25/23
AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccineMarket Watch • 10/24/23
US Food and Drug Administration accepts for review AstraZeneca's Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)Business Wire • 10/24/23
Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead StockInvestors Business Daily • 10/18/23
Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African AncestryBusiness Wire • 10/18/23
SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer CarePRNewsWire • 10/18/23
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLLPRNewsWire • 10/16/23